Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model
Open Access
- 3 October 2016
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (46) , 75839-75853
Abstract
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAF V600E targeted inhibition in a novel syngeneic murine glioma model Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma modelKeywords
This publication has 46 references indexed in Scilit:
- EGFR blockade prevents glioma escape from BRAFV600E targeted therapyOncotarget, 2015
- BRAF Mutation and CDKN2A Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade GliomaJournal of Clinical Oncology, 2015
- Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?Expert Opinion on Pharmacotherapy, 2014
- Immunocompetent murine models for the study of glioblastoma immunotherapyJournal of Translational Medicine, 2014
- Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin LesionsPLOS ONE, 2013
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaNew England Journal of Medicine, 2012
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsNew England Journal of Medicine, 2012
- Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomasNeuro-Oncology, 2010
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 TrialJournal of Clinical Oncology, 2010
- Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinomaGenes & Development, 2003